Exane BNP Paribas initiated coverage on Zoetis with a new price target
$ZTS
Biotechnology: Pharmaceutical Preparations
Health Care
Exane BNP Paribas initiated coverage of Zoetis with a rating of Outperform and set a new price target of $237.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/17/2025 | $155.00 | Outperform → Market Perform | Leerink Partners |
| 6/18/2025 | $160.00 | Buy → Hold | Stifel |
| 12/2/2024 | $215.00 | Outperform | Leerink Partners |
| 7/25/2024 | $220.00 | Buy | BTIG Research |
| 1/12/2024 | $195.00 → $215.00 | Buy | Stifel |
| 12/19/2023 | $230.00 | Buy | Jefferies |
| 12/7/2023 | $237.00 | Outperform | Exane BNP Paribas |
| 9/6/2023 | $230.00 | Buy | HSBC Securities |
10-Q - Zoetis Inc. (0001555280) (Filer)
8-K - Zoetis Inc. (0001555280) (Filer)
8-K - Zoetis Inc. (0001555280) (Filer)
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species. Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o
Leerink Partners downgraded Zoetis from Outperform to Market Perform and set a new price target of $155.00
Stifel downgraded Zoetis from Buy to Hold and set a new price target of $160.00
Leerink Partners initiated coverage of Zoetis with a rating of Outperform and set a new price target of $215.00
Reports Revenue of $2.4 Billion, Growing 1%, and Net Income of $721 Million, or $1.63 per Diluted Share, Increasing 6% and 9%, Respectively, on a Reported Basis for Third Quarter 2025 Delivers 4% Organic Operational Growth in Revenue and 9% Organic Operational Growth in Adjusted Net Income for Third Quarter 2025 Reports Adjusted Net Income of $754 Million, or Adjusted Diluted EPS of $1.70, for Third Quarter 2025 Revises Full Year 2025 Revenue Guidance to $9.400 - $9.475 Billion with Organic Operational Revenue Growth of 5.5% to 6.5% Based on Broader Macro Trends and the Operational Environment Narrows Full Year 2025 Guidance for Organic Operational Growth in Adjusted Net Income
Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic) to succeed Dr. Polzer in this role, effective January 1, 2026. Dr. Esch currently serves as Senior Vice President of Global Therapeutics at Zoetis and joined Zoe
Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Portela® (relfovetmab), making it the first monoclonal antibody (mAb) therapy with a three-month dosing interval approved for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor (NGF), which is a key mediator of OA pain and inflammation. In September of this year, the Committee for Veterinary Medicinal Products (CVMP) recommended granting marketing authorization based on a positive benefit-risk balance of the safety and efficacy data submitted. In a
Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic) to succeed Dr. Polzer in this role, effective January 1, 2026. Dr. Esch currently serves as Senior Vice President of Global Therapeutics at Zoetis and joined Zoe
Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board. Ms. Tilenius is a serial entrepreneur and has founded several healthcare companies, including most recently a stealth company in the longevity AI space. Previously, she founded Vida Health, Inc., a leading B2B chronic care platform focusing on diabetes and obesity, and scaled it nationally for Fortune 500 companies, large payers and healthcar
Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He will serve on the Board's Quality and Innovation Committee. "Dr. Stetter brings invaluab
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
Reports Revenue of $2.4 Billion, Growing 1%, and Net Income of $721 Million, or $1.63 per Diluted Share, Increasing 6% and 9%, Respectively, on a Reported Basis for Third Quarter 2025 Delivers 4% Organic Operational Growth in Revenue and 9% Organic Operational Growth in Adjusted Net Income for Third Quarter 2025 Reports Adjusted Net Income of $754 Million, or Adjusted Diluted EPS of $1.70, for Third Quarter 2025 Revises Full Year 2025 Revenue Guidance to $9.400 - $9.475 Billion with Organic Operational Revenue Growth of 5.5% to 6.5% Based on Broader Macro Trends and the Operational Environment Narrows Full Year 2025 Guidance for Organic Operational Growth in Adjusted Net Income
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the fourth quarter of 2025. The dividend will be paid on Tuesday, December 2, 2025, to all holders of record of the Company's common stock as of the close of business on Friday, October 31, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock producers. T
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, November 4, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay of the webcast will be made available on November 4, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular p